Ramamohan V, Mladsi D, Ronquest N, Boklage S. A cost-consequences analysis of inpatient tolvaptan compared with fluid restriction among CHF patients with hyponatremia. Poster presented at the 2015 AMCP Nexus; October 26, 2015. Orlando, FL. [abstract] J Manag Care Pharm. 2015 Oct; 21(10-a):S53.
Dalal AA, Patel JP, D'Souza A, Farrelly E, Nagar S, Shah M. Impact of COPD exacerbation frequency on costs for a managed care population. J Manag Care Pharm. 2015 Jul;21(7):575-83.
Korsnes JS, Davis KL, Ariely R, Bell C, Mitra D. Health care resource utilization and costs associated with nonfatal major adverse cardiovascular events. J Manag Care Pharm. 2015 Jun;21(6):443-50.
DaCosta Byfield S, McPheeters JT, Burton T, Nagar SP, Hackshaw MD. Persistence and compliance among US patients receiving pazopanib or sunitinib as first-line therapy for advanced renal cell carcinoma. J Manag Care Pharm. 2015 Jun;21(6):515-22.
Maglinte G, Graham C, Schwartzberg L, Price T, Knox H, Hechmati G, Hjelmgren J, Barber B, Fakih M. Economic analysis of panitumumab versus cetuximab in chemorefractory patients with wild-type KRAS metastatic colorectal cancer. Poster presented at the 2015 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 9, 2015. San Diego, CA. [abstract] J Manag Care Pharm. 21(4a):S11-2.
Wilson M, Mody R, Ursan I, Carr S. The budgetary impact of vedolizumab in the management of moderately to severely active ulcerative colitis and Crohn's disease in the United States. Poster presented at the 2015 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 7, 2015. San Diego, CA. [abstract] J Manag Care Pharm. 21(4a):S57.
Patel J, Coleman A, Wilson M, McDade C, Carr S, Earnshaw S. Budgetary impact on a U.S. health plan after adopting umeclidinium/vilanterol (UMEC/VI) for the management of moderate-to-severe COPD. Poster presented at the 2015 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 7, 2015. San Diego, CA. [abstract] J Manag Care Pharm. 2015 Apr 7; 21(4a):S55.
Wang T, Meyers J, Davis K, Madhwani S, Boklage S. Patterns of H. pylori treatment and testing for patients in a commercially insured population. Poster presented at the 2015 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 1, 2015. San Diego, CA. [abstract] J Manag Care Pharm. 2015 Apr; 21(4-a):S11.
Talbird SE, Graham JB, Mauskopf JA, Masseria C, Krishnarajah G. Impact of tetanus, diphtheria, and acellular pertussis (Tdap) vaccine use in wound management on health care costs and pertussis cases. J Manag Care Pharm. 2015 Jan;21(1):88-99.
Hansen RN, Hackshaw MD, Nagar SP, Arondekar B, Deen KC, Sullivan SD, Ramsey SD. Health care costs among renal cancer patients using pazopanib and sunitinib. J Manag Care Pharm. 2015 Jan;21(1):37-44.
Hackshaw MD, Nagar SP, Parks DC, Miller LA. Persistence and compliance with Pazopanib in patients with advanced renal cell carcinoma within a U.S. administrative claims database. J Manag Care Pharm. 2014 Jun;20(6):603-10.
Kimball AB, Schenfeld J, Accortt NA, Anthony MS, Rothman KJ, Pariser D. Incidence rates of malignancies and hospitalized infections events in psoriasis patients with or without treatment and a general population in the US: 2005-2009. Br J Dermatol. 2014 Feb;170(2):366-73. doi: 10.1111/bjd.12744.
Brown TM, Siu K, Walker D, Pladevall-Vila M, Sander S, Mordin M. Development of a conceptual model of adherence to oral anticoagulants to reduce risk of stroke in patients with atrial fibrillation. J Manag Care Pharm. 2012 Jun 1;18(5):351-62.
Tennis P, Gelfand JM, Rothman KJ. Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors. Br J Dermatol. 2011 Sep 1;165(3):465-73.
Carsin AE, Sharp L, Comber H. Geographical, urban/rural and socioeconomic variations in nonmelanoma skin cancer incidence: a population-based study in Ireland. Br J Dermatol. 2011 Apr;164(4):822-9. doi: 10.1111/j.1365-2133.2011.10238.x
Arana A, Wentworth CE, Fernandez-Vidaurre C. Incidence of cancer in the context of atopic dermatitis: reply from authors. Br J Dermatol. 2011;164(4):896-7.
Arana A, Wentworth CE, Fernández-Vidaurre C, Schlienger RG, Conde E, Arellano FM. Incidence of cancer in the general population and in patients with or without atopic dermatitis in the U.K. Br J Dermatol. 2010;163(5):1036-43.
Bell C, Graham JB, Earnshaw S, Oleen-Burkey MK, Castelli-Haley J, Johnson K. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data. J Manag Care Pharm. 2007 Apr 1;13(3):245-61.
Stevens KJ, Brazier JE, McKenna SP, Doward LC, Cork MJ. The development of a preference-based measure of health in children with atopic dermatitis. Br J Dermatol. 2005 Aug 1;153(2):372-7.
Cvetkovski RS, Rothman KJ, Olsen J, Mathiesen B, Iversen L, Johansen JD, Agner T. Relation between diagnoses on severity, sick leave and loss of job among patients with occupational hand eczema. Br J Dermatol. 2005 Jan 1;152(1):93-8.
Whalley D, McKenna SP, Dewar AL, Erdman RA, Kohlmann T, Niero M, Cook SA, Crickx B, Herdman MJ. A new instrument for assessing quality of life in atopic dermatitis: international development of the Quality of Life Index for Atopic Dermatitis (QoLIAD). Br J Dermatol. 2004 Feb 1;150(2):274-83.
McKenna SP, Cook SA, Whalley D, Doward LC, Richards HL, Griffiths CE, van Assche D. Development of the PSORIQoL, a psoriasis-specific measure of quality of life designed for use in clinical practice and trials. Br J Dermatol. 2003 Aug 1;149(2):323-31.
Ackerman SJ, Mordin M, Reblando J, Xu X, Schein J, Vallow S, Brennan M. Patient-reported utilization patterns of fentanyl transdermal system and oxycodone hydrochloride controlled-release among patients with chronic nonmalignant pain. J Manag Care Pharm. 2003 May 1;9(3):223-31.
Caro JJ, Ward A, Craig T, Huybrecht K, Arana A, Wait S, Eleftheriou A. Impact of thalassemia major on patients and their families. Acta Haematol. 2002;107(3):150-7.
Girman CJ, Hartmaier SL, Thiboutot D, Johnson J, Barber B, Demuro-Mercon C. Development of an acne-specific quality of life questionnaire. Poster presented at the British Society for Investigative Dermatology Annual Meeting; April 1995. [abstract] Br J Dermatol. 1995 Apr; 132(4):631-60. doi: 10.1111/j.1365-2133.1995.tb08724.x